Jury rules in favor of Monsanto in Philadelphia trial

In a recent product liability trial held in Philadelphia, a jury ruled in favor of Monsanto regarding its Roundup™ product. This decision marks the 14th favorable outcome for the company in the last 20 trials, reinforcing its legal strategy of relying on scientific and regulatory evidence. Monsanto stated that the plaintiff did not successfully demonstrate that Roundup™ caused the alleged injuries, aligning with scientific consensus and regulatory assessments that deem the product non-carcinogenic. The ruling follows a favorable decision from the Third Circuit Court of Appeals in the case of Schaffner v. Monsanto, which determined that state-based failure-to-warn claims are preempted by federal law. The U.S. EPA has consistently concluded that Roundup™ does not cause cancer and has approved its product labeling without any cancer-related warnings. This legal precedent is expected to be applied to other ongoing Roundup™ cases. Monsanto is committed to advocating for legislation that supports the safety of pesticides reviewed and registered by the U.S. EPA. The company emphasizes the importance of maintaining regulatory clarity to protect agricultural tools deemed safe by experts. Without such legislative certainty, Monsanto warns that the litigation industry may continue to challenge these products. The company remains steadfast in its defense of Roundup™ products, which are essential for farmers in producing affordable food. Monsanto's ongoing legal battles and legislative efforts reflect its determination to uphold the safety and efficacy of its agricultural products in the face of public scrutiny and legal challenges.